Genetic risk for fatal blood clots identified in IBD patients

November 11, 2020

LOS ANGELES (Nov. 11, 2020) -- Blood clots are the biggest cause of death in patients with inflammatory bowel disease (IBD) -- ulcerative colitis or Crohn's disease. In a retrospective study recently published in the journal Gastroenterology, Cedars-Sinai investigators found that a combination of rare and common genetic variants in some IBD patients significantly increased their risk of developing clot-causing thromboembolic diseases.

"The genetic signature we identified more than doubled the risk of developing potentially fatal blood clots in approximately 1 in 7 IBD patients," said Dermot P. McGovern, MD, PhD, the Joshua L. and Lisa Z. Greer Chair in Inflammatory Bowel Disease Genetics and the study's senior author.

In general, several factors can contribute to an individual's chance of having dangerous blood clots form in their body, including hospitalization, surgery, age and pregnancy.

"While the risk for blood clots in IBD patients could be attributed to episodes of severe inflammation in the gastrointestinal tract that led to surgery, or to a side-effect of some medications, very little was known about the impact of genetics on that risk," said McGovern.

Researchers used whole genome sequencing and genotyping to assess 792 IBD patients and then identify patterns associated with the development of venous or arterial thromboembolisms. Investigators at the Broad Institute of MIT and Harvard in Cambridge, Massachusetts, and Tohoku University in Sendai, Japan, also contributed to the study.

"We found that rare genetic variations which have a big impact on blood clot risk in IBD patients, combined with more common genetic markers that have less of an impact, allowed us to more accurately predict the development of clots than looking at just one of those influences alone," said Takeo Naito, PhD, first author of the study and a postdoctoral scientist at Cedars-Sinai.

"Also, patients who had both the rare and common genetic fingerprints developed more serious thromboembolic diseases," said Naito.

The ability to identify IBD patients who are at high risk for developing life-threatening blood clots could lead to improvements in treatment.

"Understanding the influence of the small and large genetic variants we identified would enable physicians to provide more precise or personalized medical care. For example, it might be wise to provide regular anticoagulant therapy for some IBD patients or to avoid using certain therapeutic drugs," said McGovern.

The new IBD genetic information has the potential to help some of the sickest COVID-19 patients, according to McGovern.

"Beyond IBD, we believe this approach could be used to identify people at high-risk of developing clots including, people who become infected with SARS-COV-2, where blood clotting has been associated with the most severe cases."
DISCLOSURES: Cedars-Sinai and Dr. Dermot McGovern have financial interests in Prometheus Biosciences Inc., a company which has access to the data and specimens in Cedars-Sinai's MIRIAD Biobank (including the data and specimens used in this study.) Prometheus Biosciences seeks to develop commercial products.

Read more in Discoveries magazine: A Gut Check for Precision Medicine

Cedars-Sinai Medical Center

Related Inflammatory Bowel Disease Articles from Brightsurf:

People with inflammatory bowel disease still die earlier despite increase in life
A study comparing life expectancy of people with inflammatory bowel disease (IBD) and without found that, while life expectancy increased for both groups, people with IBD generally died sooner.

Cell therapy designed to treat inflammatory bowel disease
The UPV/EHU's NanoBioCel research group has for many years been developing systems enabling cells to be used as drugs.

Team develops wearable sensor to help people with inflammatory bowel disease
University of Texas at Dallas researchers have designed a wearable device that monitors sweat for biomarkers that could signal flare-ups of inflammatory bowel disease (IBD).

Antibiotics associated with increased risk of inflammatory bowel disease
Antibiotics use, particularly antibiotics with greater spectrum of microbial coverage, may be associated with an increased risk of new-onset inflammatory bowel disease (IBD) and its subtypes ulcerative colitis and Crohn's disease.

Yes, inflammatory bowel disease and celiac disease are linked
A systematic review and meta-analysis that has determined there is a nine-fold increased risk of having IBD for patients with a previous diagnosis of celiac disease.

The effects of inflammatory bowel disease on pregnancy
Inflammatory bowel disease (IBD) -- including Crohn's disease and ulcerative colitis -- often affects women of childbearing age.

5 major advances in inflammatory bowel disease (IBD) treatment
Summary of five impactful studies to be presented at the Crohn's & Colitis Congress, a partnership of the Crohn's & Colitis Foundation and the American Gastroenterological Association (AGA).

Researchers identify a possible cause and treatment for inflammatory bowel disease
In a study published online in PNAS on Jan. 20, 2020, Prof.

Does inflammatory bowel disease carry certain risks during pregnancy?
Pregnant women with inflammatory bowel disease (IBD) are more likely to undergo delivery by Caesarean section and face certain risks during pregnancy, according to an analysis published in Alimentary Pharmacology & Therapeutics.

Inhibiting a protease could improve the treatment of inflammatory bowel disease
Scientists at the CNIC and CSIC have identified a function of a protease that could be the future target of drugs to treat inflammatory bowel disease.

Read More: Inflammatory Bowel Disease News and Inflammatory Bowel Disease Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to